Clinical Trials Logo

Postprandial Hypoglycemia clinical trials

View clinical trials related to Postprandial Hypoglycemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05676385 Completed - Clinical trials for Postprandial Hypoglycemia

Glucose Response to a Formula for Patients at Risk of Hypoglycaemia

EFFECT
Start date: February 13, 2023
Phase: N/A
Study type: Interventional

This study assesses the glycemic responses to several nutritional products.

NCT ID: NCT04836273 Completed - Clinical trials for Postprandial Hypoglycemia

Treatment of Post-bariatric Hypoglycaemia

SHERRY
Start date: August 20, 2021
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, single-centre phase II study aiming to evaluate the efficacy, safety and tolerability of self-administered subcutaneous 120 µg dasiglucagon with an investigational trial device (i.e. a multi-dose reusable pen) for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass (RYGB) surgery. The study is divided into an in-patient and out-patient part. The primary aim of the study is to compare the effects of self-administered 120 µg dasiglucagon versus placebo on continuous glucose monitoring (CGM)-assessed time spent in hypoglycaemia in RYGB-operated individuals in an out-patient setting.

NCT ID: NCT04330196 Completed - Clinical trials for Roux-en-Y Gastric Bypass

Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.

DEEP1C
Start date: July 8, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the effect of the natural course of postprandial hypoglycemia vs. a postprandial euglycaemic condition on driving performance in individuals with confirmed postprandial hyperinsulinaemic hypoglycaemia after gastric-bypass surgery.

NCT ID: NCT03984370 Completed - Clinical trials for Postprandial Hypoglycemia

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Start date: September 18, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.

NCT ID: NCT03200782 Completed - Bariatric Surgery Clinical Trials

Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Hypo-BEAR
Start date: May 30, 2017
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate whether hypoglycaemia observed after food intake in bariatric patients can be either influenced by an SGLT2 inhibitor, empagliflozin, or via inhibition of inflammation with an human interleukin-1 receptor antagonist (IL1-RA, anakinra).

NCT ID: NCT01162499 Completed - Clinical trials for Postprandial Hypoglycemia

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

Start date: April 2010
Phase: N/A
Study type: Interventional

It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia. The investigators have shown that glucagon-like peptide-1 (GLP-1) secretion in response to a glucose load is increased in children with Post-prandial hypoglycemia (PPH). This is a proof of concept study to investigate the causative role of GLP-1 in the pathophysiology of PPH after fundoplication by evaluating the effects of GLP-1 receptor antagonism on metabolic variables after a mixed meal. Hypothesis: In children with post-prandial hypoglycemia after fundoplication, antagonism of the GLP-1 receptor by exendin-(9-39) will elevate nadir blood glucose levels after a meal challenge and prevent post-prandial hypoglycemia.